Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis

被引：16

作者：

Miura, Noriyoshi ^{[1
,2
]}

Mori, Keiichiro ^{[1
,3
]}

Mostafaei, Hadi ^{[1
,4
]}

Quhal, Fahad ^{[1
,5
]}

Motlagh, Reza Sari ^{[1
]}

Abufaraj, Mohammad ^{[1
,6
]}

Pradere, Benjamin ^{[1
,7
]}

Aydh, Abdulmajeed ^{[1
,8
]}

Laukhtina, Ekaterina ^{[1
,9
]}

D'Andrea, David ^{[1
]}

Saika, Takashi ^{[2
]}

Shariat, Shahrokh F. ^{[1
,6
,9
,10
,11
,12
,13
,14
]}

机构：

[1] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria

[2] Ehime Univ, Dept Urol, Grad Sch Med, Matsuyama, Ehime, Japan

[3] Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan

[4] Tabriz Univ Med Sci, Res Ctr Evidence Based Med, Tabriz, Iran

[5] King Fahad Specialist Hosp, Dept Urol, Dammam, Saudi Arabia

[6] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan

[7] Univ Hosp Tours, Dept Urol, Tours, France

[8] King Faisal Med City, Abha, Saudi Arabia

[9] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia

[10] Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA

[11] Univ Texas Southwestern, Dept Urol, Dallas, TX 75390 USA

[12] Karl Landsteiner Inst Urol & Androl, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

[13] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic

[14] European Assoc Urol Res Fdn, Arnhem, Netherlands

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 25卷 / 11期

关键词：

Prostate cancer; Testosterone; Meta-analysis; Androgen receptor-targeted agents; Castration-resistant; BODY-MASS INDEX; EXPLORATORY ANALYSIS; SERUM TESTOSTERONE; DOUBLE-BLIND; MEN; CHEMOTHERAPY; ABIRATERONE; ENZALUTAMIDE; PREDNISONE; SURVIVAL;

D O I：

10.1007/s10147-020-01747-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction This systematic review and meta-analysis aimed to assess the prognostic value of testosterone in patients with castration-resistant prostate cancer (CRPC). Materials and methods PubMed, Web of Science, and Scopus databases were systematically searched until December 2019, according to the Preferred Reporting Items for Systemic Review and Meta-analysis statement. The endpoints were progression-free survival (PFS) and overall survival (OS). Results We identified 11 articles with 4206 patients for systematic review and nine articles with 4136 patients for meta-analysis. Higher testosterone levels were significantly associated with better OS (pooled HR 0.74, 95% CI 0.58-0.95) and better PFS (pooled HR 0.51, 95% CI 0.30-0.87). Subgroup analyses based on the treatment type revealed that higher testosterone levels were significantly associated with better OS in CRPC patients treated with androgen receptor-targeted agents (ARTAs) (pooled HR 0.64, 95% CI 0.55-0.75), but not in those treated with chemotherapy (pooled HR 0.78, 95% CI 0.53-1.14). Conclusion This meta-analysis demonstrated that the PFS and OS were significantly greater in patients with CRPC in those with higher testosterone levels than that of those with lower testosterone levels. In the subgroup analyses, lower testosterone levels were a consistently poor prognostic factor for OS in patients treated with ARTAs, but not in those treated with chemotherapy. Therefore, higher testosterone levels could be a useful biomarker to identify patient subgroups in which ARTAs should be preferentially recommended in the CRPC setting.

引用

页码：1881 / 1891

页数：11

共 38 条

[1] How to obtain the P value from a confidence interval [J].